title: Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
abstract: BACKGROUND
  There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis.
  
  
  METHODS
  Patients with moderate-to-severe plaque psoriasis identified in a healthcare claims database completed a survey regarding experience with psoriasis treatments and preferred dosing frequency. Survey questions regarding preferences were posed in two ways: (1) by likelihood of choosing once per week or 2 weeks, or 12 weeks; and (2) by choosing one option among once every 1-2 or 3-4 weeks or 1-2 or 2-3 months. Data were analyzed by prior biologic history (biologic-experienced vs biologic-naïve, and with one or two specific biologics).
  
  
  RESULTS
  Overall, 426 patients completed the survey: 163 biologic-naïve patients and 263 biologic-experienced patients (159 had some experience with etanercept, 105 with adalimumab, and 49 with ustekinumab). Among patients who indicated experience with one or two biologics, data were available for 219 (30 with three biologics and 14 did not specify which biologic experience). The majority of biologic-naïve (68.8%) and overall biologic-experienced (69.4%) patients indicated that they were very likely to choose the least frequent dosing option of once every 12 weeks (Table 1). In contrast, fewer biologic-naïve (9.1% and 16.7%) and biologic-experienced (22.5% and 25.3%) patients indicated that they were very likely to choose the 1-week and 2-week dosing interval options, respectively. In each cohort grouped by experience with specific biologics, among those with no experience with ustekinumab, the most chosen option was 1-2 weeks. The most frequently chosen option was every 2-3 months, among patients with any experience with ustekinumab, regardless of their experience with other biologics.
  
  
  CONCLUSIONS
  The least frequent dosing interval was preferred among biologic naïve patients and patients who had any experience with ustekinumab. Dosing interval may influence the shared decision-making process for psoriasis treatment with biologics. <p><em>J Drugs Dermatol. 2017;16(3):220-226.</em></p>.
authors.forename: Mingliang
authors.initials: M
authors.lastname: Zhang
authors.forename: Chureen
authors.initials: C
authors.lastname: Carter
authors.forename: William H
authors.initials: WH
authors.lastname: Olson
authors.forename: Michael P
authors.initials: MP
authors.lastname: Johnson
authors.forename: Susan K
authors.initials: SK
authors.lastname: Brennem
authors.forename: Seina
authors.initials: S
authors.lastname: Lee
authors.forename: Kamyar
authors.initials: K
authors.lastname: Farahi
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage* / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003657:Decision Making; D004334:Drug Administration Schedule; D000068800:Etanercept / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D057240:Patient Preference / Q000706:statistics & numerical data*; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D000069549:Ustekinumab / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D001688:Biological Products; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept